Observed Signal · Sep 3, 2026 · Market Signal · Source: AbbVie · Impact: 4.5/5

AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

Executive Signal Summary

Etentamig, an investigational asset, achieved a significantly improved objective response rate (ORR, 74%) and a 60% risk reduction in disease progression or death (progression-free survival,...

MARKET SIGNALS

Track AbbVie Signals & Strategic Shifts

Polaris7 connects regulatory filings, primary sources, leadership changes, and M&A activity into structured intelligence. Set up your Polaris7 workspace to monitor relevant companies in your executive briefing.

  • Verified primary sources
  • Automated briefings
  • Instant watchlist setup
Primary Source Grounding & Direct Attribution
Direct Origin Attribution
Primary Reporting: AbbVie•Published: Sep 3, 2026

Related Market Signals & Shifts

Recent verified developments and strategic activity across this market segment.

Product & Platform LaunchOct 5, 2026

AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival...

Read assessment
BiotechOct 23, 2026

Intensity Therapeutics Presents INVINCIBLE-4 TNBC Data

Intensity Therapeutics announced that data from the first seven patients in Cohort A of the INVINCIBLE-4 study will be presented at the ESMO 2026 congress. The study evaluates INT230-6, an intratumoral therapy, in combination with neoadjuvant immunochemotherapy (NAIC) for early-stage triple-negative breast cancer (TNBC). Results showed a pathological complete response (pCR) in the breast and lymph nodes in 5 of 7 patients (71%). No invasive cancer cells in axillary lymph nodes were detected in 6 of 7 patients, despite 71% being initially node-positive. Tumor necrosis was observed in all patients after 1-2 injections. Adverse events were low grade, with dose-limiting skin reactions. The data suggest potential efficacy of INT230-6 in this setting.

Read assessment
Product & Platform LaunchSep 11, 2026

New overall survival data and treatment experience improvements reinforce the impact of RYBREVANT® (amivantamab-vmjw)-based regimens in EGFR-mutated lung cancer at WCLC 2026

Johnson & Johnson announced new overall survival data and treatment experience improvements for RYBREVANT-based regimens in EGFR-mutated lung cancer at WCLC 2026. Final overall survival results for first-line RYBREVANT plus chemotherapy in EGFR exon 20 insertion-mutated NSCLC will be featured in a Presidential Symposium. Additional findings show low rates of key treatment-related events with subcutaneous RYBREVANT FASPRO and prophylactic strategies.

Read assessment

WATCHLIST & BRIEFINGS

Receive future signals for AbbVie & competitors in your briefing

Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.

  • Regular primary-source checks
  • Structured Watchlist briefings
  • Preserves current context